Candel Therapeutics Engages in Investor Conferences
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL) is gearing up to connect with investors in an upcoming series of investor conferences, which promise insights into the company's activities and advancements in biopharmaceuticals. Under the leadership of Paul Peter Tak, M.D., Ph.D., FMedSci, who serves as Candel’s President and Chief Executive Officer, valuable discussions and presentations will be held to provide comprehensive updates to investors.
Key Conferences Scheduled
Candel will participate in several notable investor conferences throughout early September, aiming to highlight its innovative approaches in cancer treatment.
Citi's Biopharma Back to School Conference
This event will take place on September 3, 2025, at 9:00 AM ET, where investors can gain insights during a dedicated session.
Cantor Global Healthcare Conference
Scheduled for September 4, 2025, at 8:00 AM ET, this conference will include discussions on Candel's initiatives and products.
H.C. Wainwright 27th Annual Global Investment Conference
On September 5, 2025, at 7:00 AM ET, Candel's participation in this annual global event will further emphasize its commitment to innovative cancer research and therapies.
Live Webcast and Replay
For those interested in following along, live webcasts will be accessible during the presentations by navigating to the Events and Presentations section on Candel's investor page. Additionally, these webcasts will be available for replay, ensuring wider access to the valuable information shared during the events.
About Candel Therapeutics
Candel Therapeutics, Inc. is at the forefront of biopharmaceutical innovation, dedicated to advancing psychiatric and multimodal biological immunotherapies designed to aid patients in their battle against cancer. Focusing on developing therapies that provide systemic anti-tumor responses, Candel is making significant strides in cancer treatment.
The firm has made noteworthy achievements in its clinical trials, particularly with its lead product candidate, CAN-2409, which derives from its adenovirus platform. This therapy has shown promise in Phase 2a clinical trials for non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) while advancing to a crucial Phase 3 trial for localized prostate cancer. Moreover, the FDA has granted several designations to CAN-2409, underlining its potential as a critical treatment in oncology.
On the other hand, CAN-3110, originating from the herpes simplex virus platform, is undergoing a Phase 1b clinical trial for recurrent high-grade glioma (rHGG). Candel's dedication to research continues to thrive through its enLIGHTEN™ Discovery Platform, a systematic approach leveraging HSV-based technology to develop new viral immunotherapies targeting solid tumors.
Investor Contact
Theodore Jenkins
Vice President, Investor Relations and Business Development
Candel Therapeutics, Inc.
Email: tjenkins@candeltx.com
Media Contact
Ben Shannon
Vice President
ICR Healthcare
Email: CandelPR@icrhealthcare.com
Frequently Asked Questions
What is the purpose of Candel Therapeutics participating in these conferences?
Candel aims to engage with investors, provide updates on its research and development processes, and showcase its innovative therapies.
When are the conferences being held?
The conferences will be held on September 3, 4, and 5, 2025.
How can investors access the presentations?
Live webcasts of the presentations will be available through Candel's investor relations page, with replays accessible for up to 90 days following the events.
What are Candel's lead product candidates?
Candel’s lead candidates include CAN-2409 and CAN-3110, targeting various cancers using advanced viral immunotherapy platforms.
Where can I find more information about Candel Therapeutics?
More information is available on Candel's official website, which details their ongoing projects and clinical trials.
